Send your comments and tips to firstname.lastname@example.org
Beth Israel Deaconess Medical Ctr.
Boston Medical Center
Brigham and Women's Hospital
Cambridge Health Alliance
Caritas St. Elizabeth's Medical Ctr.
Children's Hospital Boston
Dana-Farber Cancer Institute
Joslin Diabetes Center
Mass. General Hospital
Mass. Health Law
New England Baptist Hospital
Short White Coat
Tufts-New England Medical Center
UMass Memorial Medical Center
University of Massachusetts
VA Medical Centers
A Healthy Blog
Running A Hospital
Nature Network Boston
SciBos - Corie Lok's blog
Nurse at small
Dr. Gwenn Is In
Healthy Children blog
Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
Short White Coat blogger Ishani Ganguli
Short White Coat blogger Jennifer Srygley
Monday, June 18, 2007
Neurontin fine funds program on drug industry influence
A Boston health educator is taking a page from the antismoking playbook.
Using money from a $430 million Pfizer Inc. settlement of illegal marketing charges, the MGH Institute of Health Professions is launching a program today to teach health care providers about drug industry influence. Just as tobacco company settlement dollars funded stop-smoking campaigns, a total of $21 million and 26 grants were earmarked nationwide to bring information about pharmaceutical marketing to prescribers and consumers.
Elissa Ladd (left), clinical assistant professor at the affiliate of Massachusetts General Hospital, won $399,400 to develop a documentary called "PERx: Prescribing Evidence-Based Therapies" and a companion website. Both are funded through fines paid by the drug giant Pfizer in 2004 when its Warner-Lambert subsidiary pleaded guilty to promoting unapproved uses for the anti-seizure drug Neurontin.
"As a practicing nurse practitioner, I was struck with the fact that pharmaceutical promotional activity was ubiquitous in our world, both as providers and consumers," Ladd said in an e-mail interview. "I felt that this promotional activity was driving the appetite in our culture for medications."
The documentary, produced by filmmaker and former pharmaceutical sales rep Kathleen Slattery-Moschkau, includes interviews with Dr. Jerry Avorn of Brigham and Women's Hospital, Dr. David Blumenthal of Mass. General, Susan M. Reverby of Wellesley College and Kenneth Kaitin of the Tufts Center for the Study of Drug Development.
While the materials were crafted as continuing medical education, the website and film are available to the public, Ladd said.
"The important outcome of this project is that prescribers of all health care professions develop an appreciation that the overuse and sometimes unnecessary prescription of expensive brand-name medications can negatively impact our overburdened health care system," she said. "Ultimately it is our patients who will suffer from the undue burden that these costs are generating."